Letrozole Clonmel Healthcare

Letrozole, the active ingredient in Letrozole Clonmel Healthcare, is an aromatase inhibitor presented as an oral tablet for oral administration. It is used to lower estrogen levels and manage estrogen receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Clonmel Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality and regulatory compliance for global distribution.

Letrozole acts on hormone‑dependent breast cancer pathways and is employed in several clinical settings. - Adjuvant therapy of early‑stage ER‑positive breast cancer: reduces risk of recurrence after surgery. - Metastatic or advanced ER‑positive breast cancer: slows disease progression in postmenopausal patients. - Hormone‑responsive breast cancer in postmenopausal women: lowers estrogen to inhibit tumor growth.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach and possible vomiting. - Headache: mild to moderate head pain. - Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Pulmonary embolism or deep‑vein thrombosis: sudden chest pain or leg swelling. - Bone fracture: increased risk due to bone loss. - Severe allergic reaction: rash, swelling, difficulty breathing. - Myocardial infarction: chest pain, shortness of breath. - Hypercholesterolemia: markedly elevated cholesterol levels.

When prescribing Letrozole, clinicians should observe several safety measures. - Monitor bone mineral density: letrozole may accelerate bone loss; consider calcium and vitamin D supplementation. - Assess liver function: periodic liver‑enzyme testing is recommended. - Evaluate cardiovascular risk: increased risk of thromboembolic events warrants caution. - Avoid use in pregnancy: teratogenic, contraindicated in pregnant women. - Discontinue if severe adverse reaction occurs: follow medical guidance promptly. - Store at ambient temperature: keep below 25 °C, retain original packaging and protect from moisture.

Letrozole can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: negates letrozole’s estrogen‑lowering effect. - Strong CYP2A6 inhibitors (e.g., ketoconazole): may raise letrozole plasma levels. - Strong CYP2A6 inducers (e.g., rifampin): may reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Tamoxifen: may diminish overall hormonal treatment benefit. - Warfarin: letrozole can increase INR; monitor coagulation parameters. - Certain antidepressants (SSRIs): may alter letrozole metabolism. - Anticonvulsants (e.g., carbamazepine): may affect drug levels and require dose adjustment.